



Correction to: Gadobutrol: A Review in Contrast-Enhanced MRI and MRA

Lesley J. Scott¹

Published online: 23 August 2018
© Springer Nature Switzerland AG 2018

Correction to: Clinical Drug Investigation 2018;38(8):773–784
<https://doi.org/10.1007/s40261-018-0674-9>

Page 774, Table 1, Ligand structure row/gadobenate dimeglumine column: The cell entry in the “Gadobenate dimeglumine” column, which previously read:

“Macrocyclic”

should read:

“Linear”

The corrected Table 1 is:

Table 1 Key chemical and physiochemical properties of selected gadolinium-based contrast agents

Property	Gadobutrol	Gadoteridol	Gadoterate meglumine	Gadobenate dimeglumine	Gadopentetate dimeglumine
Ligand structure	Macrocyclic	Macrocyclic	Macrocyclic	Linear	Linear
Charge	Non-ionic	Non-ionic	Ionic	Ionic	Ionic
Concentration (mol/L)	1	0.5	0.5	0.5	0.5
Osmolality at 37 °C (osmol/kg H ₂ O)	1.6	0.63	1.35	1.97	1.96
Relaxivities r ₁ /r ₂ in plasma at 37 °C (mmol/L/s)	5.2/6.1	4.1/5.0	3.6/4.3	6.3/9.2	4.1/4.6
Viscosity at 37 °C	4.96	1.3	2.0	5.3	2.9
Thermodynamic complex stability (log K _{eq})	21.8	23.8	25.8	22.6	22.1

Adapted from Scott [5]

The original article was corrected.

The original article can be found online at <https://doi.org/10.1007/s40261-018-0674-9>.

✉ Lesley J. Scott
demail@springer.com

¹ Springer, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand